caa a22 4500 44579447X CHVBK 20180317145120.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10620-011-1789-5 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1789-5 Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis [Elektronische Daten] [Shin Yasui, Keiichi Fujiwara, Akinobu Tawada, Yoshihiro Fukuda, Masayuki Nakano, Osamu Yokosuka] Background: Acute onset autoimmune hepatitis (AIH) shows acute presentation like acute hepatitis and does not have typical clinicopathological features of AIH. There is no gold standard for making the diagnosis. Therefore, losing the timing of starting immunosuppressive therapy, some of the cases develop into severe or fulminant form and have poor prognosis. Aims: Our aim was to elucidate the efficacy of intravenous glycyrrhizin in decreasing alanine aminotransferase (ALT) level in the early stage of acute onset AIH. Methods: Thirty-one patients were defined as acute onset AIH based on our uniform criteria, and were enrolled in this study. We prospectively treated 17 patients with sufficient doses (100ml/day) of intravenous glycyrrhizin (SNMC) at an early stage (SNMC group), and treated 14 patients of severe disease with intravenous glycyrrhizin and corticosteroids (CS) (SNMC+CS group). We examined their clinical and biochemical features and treatment responses. Results: The ALT level could be controlled at an early stage using SNMC with no significant difference compared with SNMC+CS, and responsiveness to the therapy was determined by the disease severity at the time of starting therapy rather than the time duration from onset to therapy. Recovery rate was higher in the SNMC group than in the SNMC+CS group (P=0.035). Conclusions: The early introduction of sufficient doses of SNMC might prevent disease progression in patients with acute onset AIH. SNMC can be used safely and be useful for patients with difficult-to-diagnose acute liver disease as an ‘initial' treatment tool to improve liver inflammation before starting disease-specific treatments. Springer Science+Business Media, LLC, 2011 Autoimmune hepatitis nationallicence Acute onset nationallicence Intravenous glycyrrhizin nationallicence Disease severity nationallicence AIH : Autoimmune hepatitis nationallicence SNMC : Stronger Neo-Minophagen C nationallicence CS : Corticosteroid nationallicence Yasui Shin Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Fujiwara Keiichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Tawada Akinobu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Fukuda Yoshihiro Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Nakano Masayuki Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 276-8524, Chiba, Japan aut Yokosuka Osamu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3638-3647 0163-2116 56:12<3638 2011 56 10620 https://doi.org/10.1007/s10620-011-1789-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1789-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yasui Shin Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Fujiwara Keiichi Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Tawada Akinobu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Fukuda Yoshihiro Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 700 1- Nakano Masayuki Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 276-8524, Chiba, Japan aut NATIONALLICENCE 700 1- Yokosuka Osamu Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, 260-8670, Chiba, Japan aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3638-3647 0163-2116 56:12<3638 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer